Bellevue Group Ag Affimed N.V. Transaction History

Bellevue Group Ag

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$2.67 - $3.65 $447,225 - $611,375	-167,500 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$3.05 - $4.34 $7,625 - $10,850	-2,500 Reduced 1.47%	167,500 $704,000
Q4 2018 Feb 12, 2019	BUY	$2.82 - $4.67 $479,400 - $793,900	170,000 New	170,000 $529,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $429M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.